论文部分内容阅读
克洛维斯肿瘤科学公司宣布更新PARP1和PARP2强抑制剂rucaparib治疗有BRCA基因突变的晚期卵巢癌Ⅱ期临床试验资料,证实具有令人非常信服的临床疗效。Ⅱ期临床ARIEL2试验研究了rucaparib对204名卵巢癌患者的疗效。有BRCA基因突变患者的平均无病情加重存活时间为9.4个月,生物标记物阴性者为3.7个月,临床效果十分显著。有BRCA基因突变患者82%(32/39)达到实体瘤治疗效果评价标准RECIST和肿瘤标记物CA-125测定的有效标准,只达到RECIST有效反应者为69%(27/39),疾病控制率为73%;生物标记物阴性患者疗效较差,只有21%(13/62)达到实体瘤治疗效果评价标准RECIST和肿瘤标记
The Clovis Oncology Company announced that the updated PARP1 and PARP2 strong inhibitor rucaparib treatment of advanced ovarian cancer with BRCA gene mutations in phase Ⅱ clinical trial data, confirmed with very convincing clinical efficacy. Phase II clinical ARIEL2 trial evaluated the efficacy of rucaparib in 204 ovarian cancer patients. Patients with BRCA mutations had an average progression-free survival of 9.4 months and a negative biomarker of 3.7 months, with a clinically significant effect. 82% (32/39) of patients with BRCA mutations met the criteria of RECIST and CA-125, the effective rate of which was only 69% (27/39) for RECIST effective response and disease control rate (73%). The biomarker-negative patients were less effective, and only 21% (13/62) achieved the RECIST and tumor marker